Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases



Rating:

Share or cite this content

Citations should be made in the following way:
U. KHATTRI (Bareilly, India), L. Singh (Bareilly, India), R. Tandon (Bareilly, India), G. Karki (Bareilly, India), N. Choudhry (Bareilly, India). Study of microalbuminuria in COPD patients and its association with cardiac comorbidities. 1150

Member's Comments

No comment yet.

Related content which might interest you: Cardiovascular comorbidity in severe COPD patients Source: International Congress 2017 – Markers of COPD progression Year: 2017 Impact of diabetes in patients with COPD Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Safety profile of COPD medications in COPD patients with concomitant diabetes mellitus Source: International Congress 2017 – COPD management Year: 2017 Prevalence of comorbidities in patients with COPD in south-Spain Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity Year: 2011 Relationship of hyperlipidemia to comorbidities and lung function in COPD: results of the COSYCONET cohort Source: International Congress 2017 – COPD: risk factors and prognosis Year: 2017 NT-proBNP in assessment of pulmonary hypertension in COPD patients Source: Annual Congress 2013 –COPD treatment Year: 2013 Role of comorbidities in stable COPD patients mortality Source: International Congress 2016 – Monitoring comorbidities Year: 2016 Impact of hyperglycaemia and comorbid diabetes mellitus on short and long-term outcome after COPD exacerbation Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement Year: 2013 Microalbuminuria in patients with COPD: prevalence and correlations with pulmonary parameters Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 High prevalence of undiagnosed COPD in patients with cardiovascular disease Source: Annual Congress 2009 - Risk factors for COPD Year: 2009 Cardiovascular diseases (CVD), arterial hypertension (AH) and diabetes mellitus (DM) in a cohort of 609 COPD patients: Associations with the new GOLD classification 2011 Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations Year: 2013 COPD and comorbidities Source: Annual Congress 2009 - COPD comorbidities: translational approaches Year: 2009 High prevalence of altered cardiac repolarization in patients with COPD Source: Annual Congress 2013 –Clinical physiology and functional imaging in health and disease Year: 2013 Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk? Source: Eur Respir J 2015; 46: 846-849 Year: 2015 Burden of comorbidities and NT-proBNP concentrations in stable COPD patients Source: Annual Congress 2013 –The latest insights in respiratory muscles, neuromuscular disease and comorbidities Year: 2013 Pharmacological treatment of self-reported cardiovascular comorbidity in COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 453s Year: 2007 Comparison of COPD patients with and without diabetes mellitus Source: Virtual Congress 2020 – Diagnosis and management of COPD Year: 2020 Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD Source: Eur Respir J 2008; 32: 962-969 Year: 2008 Impact of comorbidities and delay in diagnosis in elderly patients with pulmonary hypertension Source: ERJ Open Res, 4 (4) 00100-2018; 10.1183/23120541.00100-2018 Year: 2018